Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. more
Time Frame | NTLA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.66% | -2.82% | 0.15% |
1-Month Return | -18.56% | -4.22% | 1.78% |
3-Month Return | -34.4% | -9.52% | 8.7% |
6-Month Return | -47.54% | -3.45% | 12.24% |
1-Year Return | -51.83% | 5.62% | 30.9% |
3-Year Return | -88.13% | 3.8% | 30.19% |
5-Year Return | -19.33% | 39.68% | 91.72% |
10-Year Return | -38.64% | 105.02% | 203.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 43.10M | 57.99M | 33.05M | 52.12M | 36.27M | [{"date":"2019-12-31","value":74.32,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":56.99,"profit":true},{"date":"2022-12-31","value":89.87,"profit":true},{"date":"2023-12-31","value":62.55,"profit":true}] |
Cost of Revenue | 108.41M | 150.41M | 6.89M | 7.57M | 8.98M | [{"date":"2019-12-31","value":72.08,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":4.58,"profit":true},{"date":"2022-12-31","value":5.03,"profit":true},{"date":"2023-12-31","value":5.97,"profit":true}] |
Gross Profit | (65.31M) | 57.99M | 33.05M | 44.55M | 27.30M | [{"date":"2019-12-31","value":-112.62,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":56.99,"profit":true},{"date":"2022-12-31","value":76.82,"profit":true},{"date":"2023-12-31","value":47.07,"profit":true}] |
Gross Margin | (151.52%) | 100.00% | 100.00% | 85.47% | 75.26% | [{"date":"2019-12-31","value":-151.52,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":85.47,"profit":true},{"date":"2023-12-31","value":75.26,"profit":true}] |
Operating Expenses | 149.47M | 194.58M | 300.90M | 510.29M | 551.57M | [{"date":"2019-12-31","value":27.1,"profit":true},{"date":"2020-12-31","value":35.28,"profit":true},{"date":"2021-12-31","value":54.55,"profit":true},{"date":"2022-12-31","value":92.52,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (106.37M) | (136.58M) | (267.85M) | (458.16M) | (515.29M) | [{"date":"2019-12-31","value":-10636800000,"profit":false},{"date":"2020-12-31","value":-13658300000,"profit":false},{"date":"2021-12-31","value":-26785000000,"profit":false},{"date":"2022-12-31","value":-45816400000,"profit":false},{"date":"2023-12-31","value":-51529100000,"profit":false}] |
Total Non-Operating Income/Expense | 13.67M | 4.70M | 1.24M | (7.48M) | 83.93M | [{"date":"2019-12-31","value":16.29,"profit":true},{"date":"2020-12-31","value":5.6,"profit":true},{"date":"2021-12-31","value":1.48,"profit":true},{"date":"2022-12-31","value":-8.91,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (99.53M) | (134.23M) | (267.89M) | (474.19M) | (481.19M) | [{"date":"2019-12-31","value":-9953300000,"profit":false},{"date":"2020-12-31","value":-13423100000,"profit":false},{"date":"2021-12-31","value":-26789200000,"profit":false},{"date":"2022-12-31","value":-47418600000,"profit":false},{"date":"2023-12-31","value":-48119200000,"profit":false}] |
Income Taxes | (6.83M) | (8.66M) | (8.17M) | 16.02M | (49.73M) | [{"date":"2019-12-31","value":-42.66,"profit":false},{"date":"2020-12-31","value":-54.07,"profit":false},{"date":"2021-12-31","value":-51.02,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-310.4,"profit":false}] |
Income After Taxes | (92.70M) | (125.57M) | (259.72M) | (490.21M) | (431.46M) | [{"date":"2019-12-31","value":-9269800000,"profit":false},{"date":"2020-12-31","value":-12556800000,"profit":false},{"date":"2021-12-31","value":-25971800000,"profit":false},{"date":"2022-12-31","value":-49020800000,"profit":false},{"date":"2023-12-31","value":-43146000000,"profit":false}] |
Income From Continuous Operations | (99.53M) | (134.49M) | (267.81M) | (474.19M) | (481.19M) | [{"date":"2019-12-31","value":-9953300000,"profit":false},{"date":"2020-12-31","value":-13449100000,"profit":false},{"date":"2021-12-31","value":-26780800000,"profit":false},{"date":"2022-12-31","value":-47418600000,"profit":false},{"date":"2023-12-31","value":-48119200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (92.70M) | (125.57M) | (259.72M) | (490.21M) | (481.19M) | [{"date":"2019-12-31","value":-9269800000,"profit":false},{"date":"2020-12-31","value":-12556800000,"profit":false},{"date":"2021-12-31","value":-25971800000,"profit":false},{"date":"2022-12-31","value":-49020800000,"profit":false},{"date":"2023-12-31","value":-48119200000,"profit":false}] |
EPS (Diluted) | (2.11) | (2.40) | (3.76) | (6.18) | (5.41) | [{"date":"2019-12-31","value":-211,"profit":false},{"date":"2020-12-31","value":-240,"profit":false},{"date":"2021-12-31","value":-376,"profit":false},{"date":"2022-12-31","value":-618,"profit":false},{"date":"2023-12-31","value":-541,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
NTLA | |
---|---|
Cash Ratio | 6.23 |
Current Ratio | 6.73 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NTLA | |
---|---|
ROA (LTM) | -27.81% |
ROE (LTM) | -52.23% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NTLA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.18 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.82 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NTLA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 33.33 |
P/B | 1.49 |
Price/FCF | NM |
EV/R | 20.41 |
EV/Ebitda | NM |
PEG | NM |
Intellia Therapeutics Inc (NTLA) share price today is $13.56
Yes, Indians can buy shares of Intellia Therapeutics Inc (NTLA) on Vested. To buy Intellia Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NTLA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Intellia Therapeutics Inc (NTLA) via the Vested app. You can start investing in Intellia Therapeutics Inc (NTLA) with a minimum investment of $1.
You can invest in shares of Intellia Therapeutics Inc (NTLA) via Vested in three simple steps:
The 52-week high price of Intellia Therapeutics Inc (NTLA) is $34.87. The 52-week low price of Intellia Therapeutics Inc (NTLA) is $12.82.
The price-to-earnings (P/E) ratio of Intellia Therapeutics Inc (NTLA) is
The price-to-book (P/B) ratio of Intellia Therapeutics Inc (NTLA) is 1.49
The dividend yield of Intellia Therapeutics Inc (NTLA) is 0.00%
The market capitalization of Intellia Therapeutics Inc (NTLA) is $1.50B
The stock symbol (or ticker) of Intellia Therapeutics Inc is NTLA